Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) under the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director share allocations rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported. The filing details a specific increase in the notional allocation of American Depositary Shares (ADSs) for Dr. M. Slaoui and Dr. K. Slaoui (Connected Person) resulting from a revaluation of the cash element within the US Retirement Savings Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. The transaction was executed at a price of $52.97 per ADS on May 24, 2013, involving an allocation of 3 ADSs.
Investor Verification Points
- Verify the total number of ADSs held by Dr. M. Slaoui and Dr. K. Slaoui following this 3-ADS increase.
- Confirm the current market price of GSK ADSs relative to the $52.97 transaction price cited in May 2013.
- Review the full terms of the US Retirement Savings Plan to understand the mechanics of the notional revaluation.